An observational clinical study for Camrelizumab in the treatment of inoperable lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900026089

Enrollment

Unknown

Registered

2019-09-20

Start date

2019-10-01

Completion date

Unknown

Last updated

2019-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:???

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years, male or female 2. Inoperable lung cancer patients diagnosed by histopathology or cytology; 3. Voluntarily joined the study and signed the informed consent; 4. The researchers believe that treatment can be beneficial.

Exclusion criteria

Exclusion criteria: 1. Patients have a history of immunodeficiency, or have other acquired, congenital immunodeficiency diseases, or have a history of organ transplantation 2. Patients have thyroid dysfunction in the past, and in the case of medical treatment, thyroid function can not be maintained within the normal range. 3. Pregant or lactating women; 4. Patients with a history of psychotropic substance abuse who is unable to quit or has a mental disorder 5. Not suitable for inclusion according to the researcher.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactYongqian Shu

Jiangsu Province Hospital

shuyongqian@csco.og.cn+86 13951017570

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 18, 2026